Sandoz is a Switzerland‑headquartered pharmaceutical company focused on the development, manufacture, and supply of generic medicines and biosimilars. Formerly the generics and biosimilars division of Novartis, it became an independent, publicly listed company in 2023 on the SIX Swiss Exchange (with an ADR program in the US).
The company’s portfolio spans small‑molecule generics, anti‑infectives (including antibiotics), and biopharmaceuticals/biosimilars across a broad range of therapeutic areas. Sandoz operates global R&D, manufacturing, and supply networks covering active pharmaceutical ingredients (APIs) and finished dosage forms, serving healthcare systems worldwide with high‑quality, affordable medicines.